ASKA Pharmaceutical HoldingsLtd Past Earnings Performance
Past criteria checks 4/6
ASKA Pharmaceutical HoldingsLtd has been growing earnings at an average annual rate of 37.7%, while the Pharmaceuticals industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 5% per year. ASKA Pharmaceutical HoldingsLtd's return on equity is 11.7%, and it has net margins of 11.7%.
Key information
37.7%
Earnings growth rate
37.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 3.4% |
| Revenue growth rate | 5.0% |
| Return on equity | 11.7% |
| Net Margin | 11.7% |
| Next Earnings Update | 05 Nov 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How ASKA Pharmaceutical HoldingsLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 63,172 | 7,390 | 20,090 | 4,728 |
| 31 Mar 24 | 62,843 | 7,545 | 19,436 | 4,728 |
| 31 Dec 23 | 62,026 | 6,513 | 20,029 | 4,227 |
| 30 Sep 23 | 61,937 | 6,021 | 19,957 | 4,227 |
| 30 Jun 23 | 61,215 | 4,343 | 19,421 | 4,227 |
| 31 Mar 23 | 60,461 | 4,238 | 19,249 | 4,227 |
| 31 Dec 22 | 59,687 | 4,391 | 19,265 | 3,598 |
| 30 Sep 22 | 58,302 | 9,432 | 18,612 | 3,598 |
| 30 Jun 22 | 57,655 | 4,515 | 18,044 | 3,598 |
| 31 Mar 22 | 56,607 | 4,290 | 17,958 | 3,598 |
| 31 Dec 21 | 56,010 | 4,344 | 21,240 | 0 |
| 30 Sep 21 | 56,255 | -1,635 | 21,647 | 0 |
| 30 Jun 21 | 55,688 | 3,072 | 22,099 | 0 |
| 31 Mar 21 | 55,181 | 2,713 | 21,773 | 0 |
| 31 Dec 20 | 54,685 | 2,036 | 17,103 | 4,913 |
| 30 Sep 20 | 53,363 | 1,624 | 17,147 | 4,913 |
| 30 Jun 20 | 52,265 | 825 | 16,980 | 4,913 |
| 31 Mar 20 | 52,542 | 649 | 17,596 | 4,913 |
| 31 Dec 19 | 50,897 | 592 | 17,253 | 4,493 |
| 30 Sep 19 | 49,811 | 1,578 | 15,471 | 4,493 |
| 30 Jun 19 | 47,936 | 1,245 | 14,319 | 4,493 |
| 31 Mar 19 | 46,706 | 1,744 | 12,614 | 4,493 |
| 31 Dec 18 | 47,247 | 1,578 | 12,507 | 4,055 |
| 30 Sep 18 | 47,367 | 1,488 | 12,542 | 4,055 |
| 30 Jun 18 | 48,892 | 2,407 | 12,105 | 4,055 |
| 31 Mar 18 | 48,944 | 2,388 | 12,005 | 4,055 |
| 31 Dec 17 | 49,765 | 2,060 | 11,625 | 4,970 |
| 30 Sep 17 | 49,265 | 3,312 | 12,142 | 4,970 |
| 30 Jun 17 | 49,353 | 3,461 | 12,116 | 4,970 |
| 31 Mar 17 | 48,527 | 2,944 | 12,149 | 4,970 |
| 31 Dec 16 | 47,158 | 3,531 | 12,084 | 4,174 |
| 30 Sep 16 | 46,424 | 1,581 | 11,889 | 4,174 |
| 30 Jun 16 | 44,479 | 1,040 | 11,726 | 4,174 |
| 31 Mar 16 | 43,215 | 701 | 11,804 | 4,174 |
| 31 Dec 15 | 42,721 | 792 | 12,506 | 4,025 |
| 30 Sep 15 | 40,819 | 752 | 11,870 | 4,025 |
| 30 Jun 15 | 43,197 | 1,085 | 11,850 | 4,025 |
| 31 Mar 15 | 42,907 | 1,193 | 11,742 | 4,025 |
| 31 Dec 14 | 42,335 | 695 | 11,492 | 4,144 |
| 30 Sep 14 | 42,670 | 809 | 11,904 | 4,144 |
| 30 Jun 14 | 39,393 | 282 | 12,209 | 4,144 |
| 31 Mar 14 | 39,501 | 495 | 12,209 | 4,144 |
| 31 Dec 13 | 40,632 | 1,000 | 12,487 | 4,269 |
Quality Earnings: 4886 has a large one-off gain of ¥3.3B impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: 4886's current net profit margins (11.7%) are higher than last year (7.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4886's earnings have grown significantly by 37.7% per year over the past 5 years.
Accelerating Growth: 4886's earnings growth over the past year (70.2%) exceeds its 5-year average (37.7% per year).
Earnings vs Industry: 4886 earnings growth over the past year (70.2%) exceeded the Pharmaceuticals industry 24.3%.
Return on Equity
High ROE: 4886's Return on Equity (11.7%) is considered low.